Physician profile
Mark A Efird
NPI 1609832591
$11,944.35
in general payments reported to CMS, 2019-2025
47 companies · $2,151 in 2025
The $2,151 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,466 · 2022: $2,724 · 2023: $2,338 · 2024: $2,266 · 2025: $2,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,713 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,712.93 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,164.24 | 2021-2025 | |
| Abbvie INC. | $1,124.65 | 2021-2025 | |
| Lilly USA, LLC | $1,056.19 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $688.45 | 2021-2025 | |
| Novo Nordisk INC | $638.47 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $603.84 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.10 | 2021-2025 | Synjardy, Jardiance |
| Janssen Pharmaceuticals, INC | $521.65 | 2021-2022 | |
| Amgen INC. | $511.62 | 2021-2025 | Otezla, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $470.01 | 2021-2025 | |
| Astellas Pharma US INC | $377.70 | 2021-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $372.08 | 2021-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.32 | 2021-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $279.58 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $251.19 | 2023-2025 | Rexulti |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $244.79 | 2021-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company Ltd. | $236.60 | 2022 | |
| Novartis Pharmaceuticals Corporation | $185.13 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $181.50 | 2021 | |
| Idorsia Pharmaceuticals US INC | $174.27 | 2022-2023 | Quviviq |
| Abbott Laboratories | $170.56 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $160.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $160.17 | 2021-2024 | Verquvo, Capvaxive, Vaxneuvance |
| Kowa Pharmaceuticals America, INC. | $154.29 | 2021-2025 | Zoryve, Seglentis |
| Eisai INC. | $134.03 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $129.32 | 2022-2025 | Gvoke Hypopen |
| Boston Scientific Corporation | $126.97 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Lundbeck LLC | $112.12 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $102.60 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $91.10 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $77.76 | 2025 | Korlym |
| Jazz Pharmaceuticals INC. | $63.84 | 2021 | |
| Cequr Corporation | $59.89 | 2023-2025 | Cequr Simplicity |
| Teva Pharmaceuticals USA, INC. | $59.64 | 2021-2025 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.08 | 2024-2025 | Caplyta |
| Dexcom, INC. | $55.94 | 2021-2024 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $45.08 | 2022-2025 | Nuzyra |
| Genentech USA, INC. | $43.00 | 2021 | |
| Shield Therapeutics INC | $36.66 | 2023 | Accrufer |
| Mylan Specialty L.P. | $33.45 | 2021-2023 | Yupelri |
| Antares Pharma, INC. | $32.94 | 2021 | |
| Axsome Therapeutics, INC. | $17.17 | 2024 | Auvelity |
| Almatica Pharma LLC | $17.15 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.99 | 2021 | |
| Currax Pharmaceuticals LLC | $14.84 | 2021 | |
| Clarus Therapeutics INC. | $14.28 | 2021 | |
| Phadia US INC. | $13.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Efird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.